An edition of Economic assessment
(2002)
Economic assessment
celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis
by Andreas Maetzel
Share
×Close
This edition doesn't have a description yet. Can you add one?
Buy this book
| Edition | Availability |
|---|---|
1
Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis
2002, Canadian Coordinating Office for Health Technology Assessment
in English
|
aaaa
|
Book Details
Edition Notes
This overview is based on the technology report no. 23 entitled Cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis by A. Maetzel, M.D. Krahn and G. Naglie.--Cf. t. p.
"Bruce Brady and Michel Boucher (CCOHTA) are acknowledged for their significant contribution in the preparation of this overview".
At head of title: The Canadian Coordinating Office for Health Technology Assessment.
"February 2002".
Includes bibliographical references.
Classifications
The Physical Object
Edition Identifiers
Work Identifiers
Community Reviews (0)
History
- Created November 1, 2008
- 2 revisions
Wikipedia citation
×CloseCopy and paste this code into your Wikipedia page. Need help?
| December 15, 2009 | Edited by WorkBot | link works |
| November 1, 2008 | Created by ImportBot | Imported from University of Toronto MARC record |